Is NRH legal in Australia?

Raises cellular NAD by 2.5 to 10-fold within an hour in cultured mammalian cells, more than NR or NMN at equivalent concentrations, and reaches tissues in mice. It has never been given to a human being in a published trial, and it is already sold to consumers.

NRH is the reduced form of nicotinamide riboside, and it is the most potent NAD-raising molecule in this batch by a wide margin. Every number supporting that statement comes from cultured cells or from mice.

Mechanism: NRH is converted to NMNH by an ATP-dependent kinase activity found in cell lysates that is independent of NRK1 and NRK2, and NMNH is then adenylylated by NMNAT enzymes to NADH, which enters the NAD pool. Bypassing the NRK step is the proposed reason NRH outperforms NR, since NRK1 expression is rate-limiting for NR utilisation and is not required here.

Regulatory history: Not an approved drug and not an established dietary ingredient in the United States. It is sold by research-chemical and supplement vendors without any published human safety data. FDA has not evaluated it.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for NRH at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.